Literature DB >> 12451160

A longitudinal evaluation of patients' perceptions of Parkinson's disease.

Margaret Schenkman1, Toni M Cutson, Carolyn W Zhu, Kathryn Whetten-Goldstein.   

Abstract

PURPOSE: Parkinson's disease (PD) is a chronic progressive neurological disorder that frequently results in nearly total disability. This study examined changes over 3 years in patients' experiences living with PD, and explored how participants' health perceptions and predicted mortality at baseline related to their actual death by Year 3. DESIGN AND METHODS: Data were obtained from a local sample of 109 participants by in-home interviews.
RESULTS: The collected results (1) suggested a disconnection between the participants' responses to open-ended questions about the disorder, compared with their responses to questions structured by the investigators; (2) demonstrated changes in responses to structured and open-ended questions; and (3) demonstrated that respondents who declined to predict whether they would be living in 10 years were three times more likely to die by Year 3 than those who answered the question. IMPLICATIONS: Results demonstrate the importance of identifying the most important issues for the individual with PD and suggest that these issues may change over time. Results also raise issues surrounding how patients' perceptions influence the course of their disease.

Entities:  

Mesh:

Year:  2002        PMID: 12451160     DOI: 10.1093/geront/42.6.790

Source DB:  PubMed          Journal:  Gerontologist        ISSN: 0016-9013


  9 in total

1.  Minority enrollment in Parkinson's disease clinical trials.

Authors:  Myra G Schneider; Christopher J Swearingen; Lisa M Shulman; Jian Ye; Mona Baumgarten; Barbara C Tilley
Journal:  Parkinsonism Relat Disord       Date:  2008-08-09       Impact factor: 4.891

2.  Feasibility of using cranial electrotherapy stimulation for pain in persons with Parkinson's disease.

Authors:  Diana H Rintala; Gabriel Tan; Pamela Willson; Mon S Bryant; Eugene C H Lai
Journal:  Parkinsons Dis       Date:  2010-05-05

Review 3.  Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations.

Authors:  Ann M Taylor; Kristine Phillips; Kushang V Patel; Dennis C Turk; Robert H Dworkin; Dorcas Beaton; Daniel J Clauw; Monique A M Gignac; John D Markman; David A Williams; Shay Bujanover; Laurie B Burke; Daniel B Carr; Ernest H Choy; Philip G Conaghan; Penney Cowan; John T Farrar; Roy Freeman; Jennifer Gewandter; Ian Gilron; Veeraindar Goli; Tony D Gover; J David Haddox; Robert D Kerns; Ernest A Kopecky; David A Lee; Richard Malamut; Philip Mease; Bob A Rappaport; Lee S Simon; Jasvinder A Singh; Shannon M Smith; Vibeke Strand; Peter Tugwell; Gertrude F Vanhove; Christin Veasley; Gary A Walco; Ajay D Wasan; James Witter
Journal:  Pain       Date:  2016-09       Impact factor: 7.926

4.  A review of dual-task walking deficits in people with Parkinson's disease: motor and cognitive contributions, mechanisms, and clinical implications.

Authors:  Valerie E Kelly; Alexis J Eusterbrock; Anne Shumway-Cook
Journal:  Parkinsons Dis       Date:  2011-10-27

Review 5.  Falling upward with Parkinson's disease.

Authors:  Stephen A Buetow; Pablo Martínez-Martín; Brendan McCormack
Journal:  NPJ Parkinsons Dis       Date:  2017-09-13

6.  The Dominant-Subthalamic Nucleus Phenomenon in Bilateral Deep Brain Stimulation for Parkinson's Disease: Evidence from a Gait Analysis Study.

Authors:  Mario Giorgio Rizzone; Maurizio Ferrarin; Michele Maria Lanotte; Leonardo Lopiano; Ilaria Carpinella
Journal:  Front Neurol       Date:  2017-10-30       Impact factor: 4.003

7.  Self-Reported Visual Complaints in People with Parkinson's Disease: A Systematic Review.

Authors:  Iris van der Lijn; Gera A de Haan; Famke Huizinga; Fleur E van der Feen; A Wijnand F Rutgers; Catherina Stellingwerf; Teus van Laar; Joost Heutink
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

8.  Measurement tools to assess activities of daily living in patients with Parkinson's disease: A systematic review.

Authors:  Raquel Bouça-Machado; Adriana Fernandes; Carlo Ranzato; Duane Beneby; Hipólito Nzwalo; Joaquim J Ferreira
Journal:  Front Neurosci       Date:  2022-07-20       Impact factor: 5.152

9.  The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.

Authors:  Emily J Henderson; Stephen R Lord; Jacqueline C T Close; Andrew D Lawrence; Alan Whone; Yoav Ben-Shlomo
Journal:  BMC Neurol       Date:  2013-12-03       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.